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Little is known about how RNA editing operates in
cancer. Transcriptome analysis of 68 normal and
cancerous breast tissues revealed that the editing
enzyme ADAR acts uniformly, on the same loci,
across tissues. In controlled ADAR expression ex-
periments, the editing frequency increased at all
loci with ADAR expression levels according to the
logistic model. Loci-specific ‘‘editabilities,’’ i.e., pro-
pensities to be edited by ADAR, were quantifiable by
fitting the logistic function to dose-response data.
The editing frequency was increased in tumor cells
in comparison to normal controls. Type I interferon
response and ADAR DNA copy number together ex-
plained 53% of ADAR expression variance in breast
cancers. ADAR silencing using small hairpin RNA
lentivirus transduction in breast cancer cell lines led
to less cell proliferation and more apoptosis. A-to-I
editing is a pervasive, yet reproducible, source of
variation that is globally controlled by 1q amplifica-
tion and inflammation, both of which are highly prev-
alent among human cancers.
INTRODUCTION
Although intense effort is currently being dedicated to cancer
genome sequencing, comparatively little attention has been
devoted at understanding how faithful RNA sequences are to
the DNA sequences from which they were derived. mRNA is
the target of a series of post-transcriptional modifications thatCcan affect its structure and stability, one of the most relevant be-
ing RNA editing (Bass, 2002; Levanon et al., 2004; Nishikura,
2010). The most common form of RNA editing in humans, the
A-to-I type, is catalyzed by the adenosine deaminases that act
on RNA (ADARs) family of enzymes, which bind double-stranded
RNA (dsRNA) and turn adenosines into inosines at precise posi-
tions (Bass, 2002; Nishikura, 2010). Inosines are subsequently
interpreted as guanosines by the cellular transcription machin-
ery. ADAR enzymes are essential in mammals (Higuchi et al.,
2000; Wang et al., 2000) and exist in three forms: ADAR (also
known as ADAR1), which is ubiquitous and has two isoforms—
p110 is constitutive and p150 is inducible; ADARB1 (also known
as ADAR2), principally expressed in the brain; and ADARB2 (also
known as ADAR3), which contrary to ADAR and ADARB1 seems
to be enzymatically inactive (Chen et al., 2000; Savva et al.,
2012).
A-to-I edits can profoundly influence cellular functions and
regulations by altering mRNA splicing, stability, localization,
and translation, and by interfering with the binding of regulatory
RNAs (Athanasiadis et al., 2004; Rueter et al., 1999; Wang et al.,
2013). In addition to mRNA, ADAR can target non-coding RNAs
such as micro-RNAs (miRNAs), small-interfering RNAs (siRNAs),
and long non-coding RNAs (lncRNAs), affecting both their struc-
ture and activities (Blow et al., 2006; Hundley and Bass, 2010;
Kapusta et al., 2013; Kawahara et al., 2007). A-to-I editing has
been shown to occur predominantly in highly repetitive Alu se-
quences, likely because their frequency (>106) in the human
genome makes their arrangement in quasi-palindrome configu-
rations prone to RNA duplex formation highly probable (Athana-
siadis et al., 2004; Bazak et al., 2014a; Kim et al., 2004; Levanon
et al., 2004). High-throughput sequencing studies suggest that
tens of thousands to millions of positions are targeted by A-to-I
editing in the human transcriptome (Bahn et al., 2012; Ju et al.,ell Reports 13, 277–289, October 13, 2015 ª2015 The Authors 277
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Figure 1. Detection of A-to-I Editing
(A) Substitution frequencies of RDDs.
(B) Percentage of RDDs confirmed in the validation
data set, n = 15 BCs (in red), and the DARNED
database (in blue). The negative control set is
composed of 1,000 sites selected at random
positions in randomly selected Alu regions. Sites in
immunoglobulin (Ig) hyper-variable regions were
excluded; see the Supplemental Experimental
Procedures.
(C) Each dot represents a sample for which
the frequency of edited AZIN1 transcripts has
been measured with Illumina full transcriptome
sequencing (x axis) and Roche FLX amplicon
sequencing (y axis). r denotes the Spearman’s
correlation.
(D) Distribution of the 560 edited sites into func-
tional categories.
(E and F) Number of detected Alu A-to-I sites as
a function of transcriptome and exome cover-
ages, respectively. Green dots represent tumor-
matched normal samples.2011; Li et al., 2009; Park et al., 2012; Peng et al., 2012; Ramas-
wami et al., 2012, 2013), and a recent publication reports that
potentially all adenosines in specific Alu repeats undergo A-to-I
editing (Bazak et al., 2014b).
Currently, a limited number of studies on A-to-I RNA editing in
cancer have been published, with the findings pointing to a
diversity of effects. For example, in brain cancer, editing inhibits
cell growth and is reduced in glioma (Maas et al., 2001;
Paz et al., 2007) and pediatric astrocytoma (Cenci et al.,
2008). In contrast, A-to-I editing increases during chronic
myeloid leukemia progression (Jiang et al., 2013). In hepatocel-
lular carcinoma, A-to-I editing of the antizyme inhibitor 1 (AZIN1)
increases and neutralizes a key inhibitor of the polyamine syn-
thesis pathway, thereby promoting proliferation in vitro and
increasing tumor initiation and volume in a mouse xenograft
model (Chen et al., 2013). The studies published so far included
a small number of samples—an important limit given the sheer
diversity of tumor transcriptomes—and/or investigated a limited
number of editing sites. Whether the edited transcripts origi-
nated from cancer cells or other cell types, e.g., immune cells,
present in the tumor mass was not addressed. Hence, both
the magnitude and mechanisms regulating A-to-I editing in the
majority of cancers, including breast cancer (BC), remain largely
unknown.
The main objective of this study was to investigate the princi-
ples governing the A-to-I editing process in BC aswell as in other
types of cancer.278 Cell Reports 13, 277–289, October 13, 2015 ª2015 The AuthorsRESULTS
Detection and Validation of A-to-I
Editing Sites in Breast Tissue
The extent of A-to-I RNA editing in BC
was investigated by paired exome and
transcriptome sequencing of a broad
series of BC samples representing the
principal intrinsic subtypes including 17triple-negative (TN), 14 HER2-positive (HER2), 16 luminal A
(LA), and 11 luminal B (LB) tumors (Table S1). Paired exome
and transcriptome sequencing of matched, tumor-adjacent
normal tissue was performed on ten cases from this series.
RNA-DNA single nucleotide differences (RDDs) were called as
outlined in Figure S1 (details in the Supplemental Experimental
Procedures).
Overall, we detected 16,027 RDDs in one or more samples,
with all possible base changes represented (Figure 1A). Among
these, 560 RDDs were located in Alu regions, and all were of
the A-to-I type (Figure 1A; Table S2), consistent with the notion
that A-to-I editing occurs predominantly in forward-facing Alu
forming dsRNA duplexes processed by ADAR. Forty-seven
percent of the A-to-I Alu RDDs were present in the DARNED
RNA editing site database (Kiran andBaranov, 2010). In contrast,
only 2.5% of A-to-I, non-Alu RDDs and 0.6% of non A-to-I RDDs
were found in the DARNED database (Figure 1B).
Breast tissue is not well represented in the studies covered by
the DARNED database. Given that gene expression and RNA
editing frequency (defined for each sample as the ratio of the
number of RNA sequencing (RNA-seq) reads documenting
the non-reference base relative to the total number of reads
covering the site) could be regulated in a tissue specific manner,
we further validated our findings in an independent breast
series. This independent validation series included 15 BC sam-
ples with paired transcriptome and full genome sequencing
data from the Sanger Institute. The genomic coordinates of our
putative RDDs and the coordinates of 1,000 random Alu
positions were sent to the Sanger Institute without any additional
information. This blind test—based on an independent RDD
detection pipeline (Supplemental Experimental Procedures)—
confirmed 90% of the Alu RDDs, while only one of the 1,000
random Alu sites was detected in the validation series. Beyond
Alu, overlapwith the validation serieswasbelow40% (Figure 1B).
Given the low confirmation rate of RDDs located outside of Alu
regions in both the DARNED database and the independent vali-
dation series, and that the majority of human editing events are
A-to-I detected in Alu repeats (Athanasiadis et al., 2004; Bazak
et al., 2014b; Kim et al., 2004; Levanon et al., 2004), our subse-
quent analyses focused exclusively on the subset of A-to-I RDDs
located in Alu sequences. Since several works have reported the
editing of AZIN1, this target was also included in our analyses
(Chen et al., 2013; Ju et al., 2011; Li et al., 2009, 2011; Peng
et al., 2012; Qin et al., 2014; Ramaswami et al., 2012; Shah
et al., 2009).
To evaluate the accuracy of edited transcript frequencies
measured in our full transcriptome data, we generated ampli-
cons of the AZIN1 editing site region for 36 samples that
were then analyzed by an independent sequencing technology
(Roche FLX sequencer). The edit frequencies measured from
full transcriptome and amplicon sequencing were remarkably
consistent (Figure 1C) and thereby validated the accuracy of
these estimations.
The distribution of A-to-I within Alu edits according to func-
tional effect is shown in Figure 1D; functional information for all
putative and confirmed edited sites is available Table S2.
The Apparent Size of the Editome Depends on the
Transcriptome Sequencing Depth and on the Span of
Sequenced Genomic Regions
Sequencing depth is a key factor in detecting single nucleotide
variations (Bazak et al., 2014b), leading us to ask whether the
exome and RNA sequencing depths could influence the number
of detectable Alu edit sites. While this number was not depen-
dent on the exome sequencing depth, it did greatly increase
with the transcriptome coverage (Figures 1E and 1F; Table S3).
No plateau was reached in our data set, which had a maximum
coverage of 3 3 107 reads/sample. This suggests that with
higher transcriptome coverage additional A-to-I editing sites
should be detectable in the breast transcriptome.
A comparison of our results and methods with previous litera-
ture is presented in Tables S4A and S4B. This analysis revealed
that genome sequencing span is among the main factors limiting
the RDD detection. Since our DNA sequencing covered the
exome and not the entire genome, we implemented a less con-
servative editing detection pipeline bypassing the exome DNA
comparison and focusing instead the detection of A-to-I editing
on sites previously reported in the literature (Supplemental
Experimental Procedures). This DNA-free pipeline detected
59,993 A-to-I editing sites. The main variable investigated in
this paper, namely, the mean editing frequency, estimated
from these 59,993 sites or the 560 Alu sites obtained with the
DNA-based pipeline, was nearly identical (r = 0.9, p = 2 3
1016). Most of the sites detected by the DNA-free pipeline
were expressed in few samples (median, 14.7% of the samples;Cinterquartile range [IQR], 4.4%–50%) and/or edited at low fre-
quency (median, 0% of the reads; IQR, 0%–3.4%); i.e., they
were of limited interest as far as correlative analysis across a sig-
nificant fraction of the cohort is concerned and most probably
had negligible influence on cancer progression. The number of
sites dropped from 59,993 to 1,852 after filtering out positions
expressed at detectable levels in <75% of the samples and
not edited at a frequency >10% in any samples. By contrast,
applying the same filter to the DNA-based pipeline reduced the
number of sites from 560 to 455.
More A-to-I Editing Was Found in Tumor Compared to
Normal Matched Breast Tissue
To determine whether A-to-I editing is specifically altered in
BC, the mean editing frequencies across all edited sites were
compared between matched normal and tumor breast tissues
for ten caseswhere paired exomeand transcriptome sequencing
data were available for the normal tissue. We also compared the
specific edit frequency of the AZIN1 transcript determined by
high-depth amplicon sequencing (Roche FLX sequencer) be-
tween tumor and matched normal breast tissues. The global
mean editing frequency and theAZIN1 specific editing frequency
were higher in tumor compared to matched-normal breast tis-
sues (Figures 2A and 2B; Tables S3 and S5).
Normal breast samples may contain less epithelial cells;
hence, lower editing in these samples could be a trivial conse-
quence of lower editing in non-epithelial cells (e.g., adipocytes)
compared to epithelial cells. Thus, the site-averaged editing fre-
quencies across all 560Alu sites from the independent validation
series (15 BCs) were compared to eight normal breast organoids
(i.e., freshly isolated uncultured intact breast milk ducts). Editing
was higher in tumor compared to pure normal epithelial cells
(Figure 2C), which validates our findings.
Global A-to-I Editing Is Governed by ADAR Expression
and Site-Specific Editability
The general principles governing A-to-I editing in BC were inves-
tigated in multiple, matched exome-transcriptome data pairs.
The ADAR family of enzymes catalyzes A-to-I editing, leading
us to first determine their expression levels in normal and tumor
breast tissues as well as their association with editing frequency
using transcriptome sequencing data. ADAR was expressed
9-fold more than ADARB1 and >1,000-fold more than ADARB2
(p < 1016, Figure S2), which was anticipated because these
last two isoforms are principally expressed in the brain. More-
over, while ADAR expression was higher in tumor compared
to patient-matched normal breast tissues (p = 0.005, Figure
S2), an inverse borderline-significant trend was observed for
ADARB1 (p = 0.1, Figure S2).
The mean editing frequency (defined as the average editing
frequency of all 560 Alu sites) was significantly positively corre-
lated with ADAR mRNA expression levels (Spearman’s r = 0.7,
p < 2 3 1016; 40% of variance explained; Figure 3A; Table
S3), while it was weakly anti-correlated with ADARB1 expression
levels (Figure S2), as previously reported (Chen et al., 2013). The
global association detected between ADAR mRNA expression
and the mean editing frequency was also observed at individual
editing sites (Figure S2; Table S2). Considering both the highell Reports 13, 277–289, October 13, 2015 ª2015 The Authors 279
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Figure 2. A-to-I Editing and ADAR Expression in Normal and Tumor Breast Tissue
(A) Each dot represents a patient with the mean editing frequency in her normal (x axis) and her matched tumor breast tissue (y axis).
(B) Same as (A), except that the AZIN1 editing frequency measured by Roche FLX amplicon sequencing is depicted.
(C) The mean editing frequency of eight breast organoid cultures is compared to that of 15 breast tumors.
(D) Representative ADAR staining of a luminal A tumor.
(E) Zooming in (D) reveals that tumor staining (black arrows) is higher than in normal epithelium (green arrows) and lymphocytes (red arrows).
(F) Zooming further in (E) reveals a higher staining of nucleoli (black arrows).levels of ADARmRNA expression and its strong correlation with
the mean editing frequency, our further analyses were focused
on ADAR.
Editing site distribution across normal and BC tissues was
investigated by plotting the maximum edit frequency for all edit-
ing sites against the number of samples where editing of these
sites was detected (Figure 3B). These two variables were highly
correlated indicating that if a site was highly edited in one sam-
ple, it was very likely to be edited in many other samples. This
also suggested that the editing sites detected in normal tissues
are also detected in matched tumor tissues and across all BC
patients.
Sites and samples were then ordered by increasing mean
editing frequencies, and the individual editing frequencies at all
560 Alu sites in all samples were displayed as a heatmap (Fig-
ure 3C; negative controls in Figure S2). This revealed that high
editing frequencies were present in the samples with more edit-
ing sites and high ADAR expression. Conversely, samples with
lower ADAR expression had fewer edited sites, which were
edited at lower frequencies. Taken together, these data suggest
a quantitative model of A-to-I editing (Figure 3D). In this model,
turning up the ADAR expression ‘‘knob’’ leads to detectable ed-
iting at more sites and an increased editing frequency of all the
editable sites. Conversely, when ADAR expression is low, editing
is detectable at fewer sites and at a lower frequency. We pro-
pose that ‘‘editability,’’ the propensity of a position to be edited
by ADAR, depends mostly upon biophysical interactions be-280 Cell Reports 13, 277–289, October 13, 2015 ª2015 The Authorstween an individual site with its surrounding RNA sequence
and partnering as a duplex with ADAR. We show below how to
quantitatively estimate it from dose-response data.
Validation of the A-to-I Editing Model
We challenged this A-to-I editing model by inducing ADAR
expression in four breast cell lines (three tumor and one normal
tissue derived cell lines) with interferon a, a known ADAR inducer
(Patterson andSamuel, 1995). The effect of inducingADAR over-
expression on the editing frequency of AZIN1 and four of the
most edited Alu regions in the discovery series was analyzed
by amplicon sequencing (Roche FLX sequencer). These experi-
ments demonstrated: First, that the same sites were edited in all
cell lines (Figure S3; Table S6), including 90 of the 91 sites de-
tected by whole-transcriptome sequencing in vivo. Second,
that the editing frequency profiles were similar across all cell
lines (Figure S3). Third, that ADAR induction increased editing
frequencies at all edited positions (Figures 4A and S3). Fourth,
that ADAR induction and/or increase of depth of coverage
increased the number of detected editing sites (Figure 4B).
Due to deeper coverage (typically >1,0003 for the Roche FLX
sequencer) of the cell line amplicons, we identified 137 new sites
in addition to the 90 in the discovery data set, which suggests
there are likely more sites to identify in breast tissue.
We took advantage of the long reads (>300 bp) and high
coverage of the Roche FLX data to further validate our model
by applying it to thousands of individual mRNA molecules
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Figure 3. Model of A-to-I Editing
(A) Each dot represents a sample with its RNA-
seq-estimated ADAR expression on the x axis (in
log2 of fragments per kilobase per million mapped
reads), and its mean editing frequency across all
560 Alu sites on the y axis. Green dots represent
tumor-matched normal samples. The RNA-seq
expression of ADAR is highly correlated with mi-
croarrays and qRT-PCR expression (Figure S2).
(B) Each dot represents an Alu A-to-I editing site
with themaximal edit frequency across all samples
on the x axis and the number of samples in which it
was detectably edited on the y axis.
(C) Heatmap of editing frequencies across all Alu
A-to-I edit sites in all samples. Both are ordered by
increasing (down-to-up, left-to-right) mean editing
frequencies. Smoothed contour lines labels give
the percentage of edited transcripts. The bottom
panel shows corresponding ADAR expression.
Green dots represent tumor-matched normal
samples. Negative controls are presented in Fig-
ure S2.
(D) Model of A-to-I editing. Turning the ADAR
‘‘expression knob’’ clockwise increases ADAR
expression. As a result, more transcripts are edited
(red dots), and the editing frequency of all editable
sites increases accordingly (compare green versus
red bars). Moreover, the detection limit at some
sites for which editingwas previously undetectable
is passed. The detection limit depends on
sequencing coverage, which is lower on the right-
most exon. Importantly, the ranking of editing
frequencies of the different sites is unaltered by
ADAR expression.transcribed from the same DNA region in the same individual.
Focusing on one 256-bp Alu region in one cell line, 65 of 68
adenosines potentially targeted by ADAR (Figure 4C) were edi-
ted in at least one of the 2,842 mRNA molecules analyzed. The
number of edited positions per transcript was highly variable,
ranging from 0 to 26 (38% of all adenosines). As expected,
the sets of edited positions in ‘‘low-edited’’ mRNA molecules
tended to be subsets of those edited in ‘‘high-edited’’ mRNA
molecules. These findings further validate our A-to-I editing
model. Nevertheless, the editing process had a strong sto-
chastic component at the level of individual molecules. This is
at odds with the deterministic nature of editability, a quantity
defined at the level of populations of RNA transcripts. We pro-
pose to reconcile these two viewpoints by interpreting editability
as a probability of edition by ADAR.
Quantitative Estimation of Site-Specific Editability with
the Logistic Model
The dependence of site-specific editing frequencies on ADAR
protein expression in our in vitro experiments is shown in Fig-
ure 4D. Editing frequencies increase monotonously with ADAR
until a site-specific saturation threshold is reached. This sug-
gests that these frequencies could be approximated with theCell Reports 13, 277–289logistic model, f(x) = εi/(1+exp(uix)),
at each site i. The offset of the s-shaped
curve is controlled by ui and the editingfrequency at saturation by εi.We propose εi—aquantity indepen-
dent of ADAR expression—as the mathematical definition of
site-specific editability, putting this concept on a firm quantita-
tive ground.
We estimated εi and ui by fitting the logistic model to each one
of the dose-response curves shown in the above graphics. A
typical fit is shown in Figure 4E (see also Figure S4) and the
distributions of εi and ui across all sites in Figures 4F and 4G.
As expected, εi estimates are spread over the entire [0, 1] inter-
val. The ui estimates are centered around a unique value, i.e., ui
is essentially site independent. Related p values (Figure S4) are
small considering that only four points were available for each
fit. Although saturation was reached for two ADAR expression
data points in one experiment but not in the others, the estimates
obtained for independent experiments were consistent (r = 0.97,
p < 2 3 1016; Figure S4). The lower coverage of our in vivo
data was not sufficient to adequately fit the logistic model, but
εi estimated in vitro is highly correlated with the mean editing
frequency measured in vivo (Figure 4H). In vivo editing is, on
average, well below saturation (Figure 4H). Hence, the logistic
model provides an operational procedure to derive useful quan-
titative estimates of site-specific editability from dose-response
data., October 13, 2015 ª2015 The Authors 281
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Figure 4. Validation of the A-to-I Editing Model and Quantitative Estimation of Site-Specific Editability
(A) Effect of increasing ADAR expression in the cell line MCF7 on editing in four representative Alu regions and AZIN1. The full-length of sequenced regions are
shown in Figure S3 for MCF7 and three more cell lines. Complete ADAR western blots quantifications underlying the color scale are provided in Figure 5E (see
baseline t = 0 and IFN-a, t ˛ {1, 2, 5} days tracks) and in Figure S7. Increasing ADAR expression increases the editing frequency at all editable positions, as
predicted by the model of Figure 3D. Similar results were obtained for IFN-b and IFN-g (global, position-less, view Figure 5F). Arrows point at editing sites
detectable only at higher ADAR expression in our assay.
(B) Increasing sequencing coverage (x axis) or ADAR expression (color scale) increases the number of detectable editing sites (y axis). Coverage variation was
implemented by down-sampling the total pool of sequencing reads, starting from 2,0003, down to 1003, and re-running the variant detection pipeline for each
down-sampled alignment. Each data point is the mean of 30 down-sampling experiments. Error bars, SD.
(C) Editing of individual mRNAmolecules. Each black dot depicts an edited base in a given mRNAmolecule. The y axis goes from 0 to 60 and corresponds to the
adenosines in the 250-bp span that are edited in at least one of the 2,842 reads represented along on the x axis. Reads and adenosines were ordered by
decreasing editing frequencies. 185 non-edited reads were omitted from the figure.
(D) Dose-response curves for experiment in cell line BT474. ADAR was increased through IFN-a stimulation (as in A). We focused on 81 sites (color lines) with a
baseline editing frequency >2.5% in order to avoid trivial nonlinear effects caused by lack of detection at low ADAR expression.
(E) Example of a fit of the logisticmodel (line) to experimental data points (dots). The unit ofu is commensurate to the dimensionless ADAR relative expression and
ε is the fraction of edited transcripts at saturation.
(F and G) Distributions of ε and u across the 81 sites.
(legend continued on next page)
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Site-Specific Editability Is Correlated with Local
Sequence Features
We hinted that editability depends upon biophysical interactions
between an individual site with its surrounding RNA sequence
and partnering as a duplex with ADAR. This implies that editabil-
ity should be partially predictable from the sequence data, so
we sought to develop and validate a simple proof-of-principle
DNA-based statistical model for editability. The model relies on
the notions that (1) an edited site must be part of an RNA duplex,
implying that it lies within a sequence with a nearby palindromic
match, and (2) ADAR activity depends upon a specific nucleo-
tide sequence in the vicinity of the edited base (Figure 4I; Sup-
plemental Experimental Procedures). To build the model, we
analyzed the editing frequencies of 51,621 edited Alu sites
with R203 coverage from an independent sample sequenced
at very high coverage (Ramaswami et al., 2012). These sites
were then ordered by genomic position. The first half was used
to fit a statistical model of the edit frequency based on DNA
data alone. Editability scores were then computed for the sec-
ond half of the sites (not used to train the model), which turned
out to be strongly associated with the observed editing fre-
quencies (Figure 4J). Our validated statistical model supports
the notion that the editability of a given site is partly determined
by the local site-specific DNA features. Of note, the logistic fit of
dose-response data, not the DNA-based model, should be used
to estimate quantitatively editability.
Association of ADAR Expression, A-to-I Editing, and
Clinico-Pathological Variables
The relevance of ADAR expression to the A-to-I editing process
led us to analyze its tissue and cellular localization by immuno-
histochemistry (IHC). Uniform ADAR expression was detected
in cancer cells (Figures 2D–2F) but to a lesser extent in normal
cells and tumor-infiltrating lymphocytes (TILs; see Figure 2E).
Moreover, ADAR staining was markedly stronger in nucleoli (Fig-
ure 2F), in agreement with previous findings (Desterro et al.,
2003; Sansam et al., 2003).
To investigate the potential clinical impact of A-to-I editing, we
determined whether the mean editing frequency was associ-
ated with the tumor cell content (i.e., the proportion of malignant
epithelial cells, adipose, stroma, normal epithelial cells and
TILs) and/or well-established clinico-pathological parameters,
including estrogen receptor, progesterone receptor, the prolifer-
ation marker Ki67, HER2 status, tumor size, nodal status, and
histological grade. The mean editing frequency was positively
correlated with the percentage of TILs (Spearman’s correlation
r = 0.3, p = 0.02), tumor size (r = 0.3, p = 0.01), and HER2 IHC
staining (r = 0.3, p = 0.01; Figure S5; Tables S1 and S3). Multivar-
iate analysis of this data set suggests that TILs andHER2 IHC are(H) The 81 edited sites are depicted as dots with the corresponding εi estimates d
on the y axis.
(D)–(H) are part of a more comprehensive analysis presented in Figure S4.
(I) DNA-based statistical model of editability. The model included three paramete
surrounding the editing site (green dot) within the 2,501-bp sequence surrounding
from this best alignment; (3) the 20 nucleotides surrounding the editing site. The
frequencies of half of 51,621 Alu editing sites with coverageR203 previously id
(J) Observed editing frequencies versus editabilities predicted from DNA for valid
Cdependent variables in their association with editing frequency
(Figure S5).
To circumvent our limited sample size, correlations between
these variables and ADAR expression were assessed in a large
cohort of 787 BC patients with HER2 analyzed by IHC (Curtis
et al., 2012). TILs were not scored in this series so the level
of Signal Transducer and Activator of Transcription 1 (STAT1)
expression, a proxy for type I interferon response, was used
instead. This independent BC series confirmed an association
between ADAR and STAT1 expression but not for HER2 status
or tumor size (Figure S5). The lack of an association with estro-
gen receptor, Ki67, and HER2 indicates that ADAR expression
is not correlated with a specific BC subtype beyond their link
with the adaptive immune response.
The Interferon Response and Gains in ADAR Copy
Number Independently Control A-to-I Editing in Cancer
The biological processes potentially associated with RNA editing
were investigated by searching for genes whose expression had
a strong positive correlation with the mean editing frequency
(details in the Supplemental Experimental Procedures). Remark-
ably, 62 of the 85 genes identified were located on chromo-
some 1q (p = 1066). Since ADAR is located on chromosome
1q, we next used SNP array data to determine ADAR copy
numbers in our samples. ADAR amplification was frequent in
our series (44%) and correlated with high mean editing fre-
quencies (Figure 5A).
Chromosome 1q contains hundreds of genes and therefore its
amplification could have a systemic impact on the BC transcrip-
tome (Curtis et al., 2012). Therefore, we further characterized
the genes correlated with editing that were independent from
1q amplification. First, the microarray expression data were
adjusted for 1q copy number to remove any potential confound-
ing effects of ADAR amplification, and then gene set analysis
was performed (Efron and Tibshirani, 2007) to identify canonical
pathways associated with the mean editing frequency. The 13
significant pathway gene sets revealed by this analysis were all
involved in interferon responses, interferon-related DNA and
RNA sensing, and lymphocyte biology (Figure S6). We also
investigated gene sets with shared transcription factor binding
motifs between their promoters. The seven significant gene
sets identified were overwhelmingly related to NFkB and the
interferon response, including the Interferon Response Factors
IRF1, IRF2, and IRF7 (Figure S6). To further investigate the rela-
tionship between interferon-related genes and ADAR expres-
sion, the median expression levels of STAT1 (Figure 5B) and
389 type I interferon-inducible genes (Figure S6) derived from
ten microarray studies (Schoggins et al., 2011) were measured.
The expression of STAT1 and the 389 genes were positivelyerived from the BT474 cell lines on the x axis and their in vivo editing frequency
rs: (1) the best Smith-Waterman global alignment score of the 51-bp sequence
the editing site on the reverse strand; (2) the distance separating the editing site
se 1 + 1 + 20 = 22 variables were fitted with a linear model against the editing
entified (Ramaswami et al., 2012).
ation sites.
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Figure 5. ADAR Amplification and the Interferon Response Are Independent Predictors of ADAR Expression in Cancer
(A) The top panel shows the frequencies of amplifications/deletions along chromosome 1 in our series. The middle panel shows the genes whose expression is
highly associated with that of ADAR. Nineteen genes not located on chr1 are omitted. The bottom panel shows the Spearman’s correlation coefficient and
associated p values of non-segmented copy-number array probes with the sample-wise mean editing frequencies.
(B) Dots represent tumor samples, with STAT1 expression on the x axis and ADAR expression on the y axis.
(C) Same as (B) with ADAR expression adjusted for ADAR copy number.
(D) Association p values of ADAR copy number and STAT1 expression with ADAR expression increase in a multivariate analysis, demonstrating that ADAR
expression is independently associated with these two variables.
(E) Seven breast cancer cell lines were exposed to interferon a, b, and g for 1, 2, and 5 days. Western blots quantifications are depicted for each cell line,
interferon, and time. Because expression dynamic ranges vary among cell lines, each line has its own color scale extending from low expression in green to high
expression in red. The underlying gels are presented in Figure S7 and blot quantification in Table S6. Corresponding mRNA RT-PCR expression data are shown
Figure S7 and detailed Table S7.
(F) Editing frequencies in the absence of treatment (x axis) versus interferon treatment (y axis). Points depict the editing sites in AZIN1 and the four Alu regions of
Figure S3. Points are above the identity line x = y (black diagonals); i.e., interferons increase editing frequencies at all sites. Library preparation failed for MCF7/
IFN-g at 5 days. Limited sequencing coverage precluded detection of some editing events for MDA-MB-231, t = 0 and t = 1 days.associated with ADAR expression, suggesting that increased
editing was part of a broader type I interferon response related
to the chronic inflammatory state in cancer.
The respective roles of ADAR copy number and STAT1
expression (as a proxy for interferon response) in the A-to-I edit-
ing process were further defined using multivariate analysis
to demonstrate that they are independently associated with
ADAR expression (Figures 5B–5D). STAT1 was correlated with
ADAR expression (Figure 5B), and this correlation could be
strengthened by adjusting ADAR expression for ADAR DNA
copy number (Figures 5C and 5D). Taken together, STAT1 and
ADAR copy number explained 53% of ADAR expression varia-284 Cell Reports 13, 277–289, October 13, 2015 ª2015 The Authorstion. The independent effect of type I interferon response and
ADAR amplification was also supported by measuring the
constitutive p110 and interferon-inducible p150 ADAR isoforms
(Figure S6). STAT1 expression was more strongly correlated
with p150 than p110, and, conversely, ADAR copy number
was more strongly correlated with p110 than p150.
While ADAR amplification is likely limited to malignant epithe-
lial cells, the type-I interferon effect could be principally medi-
ated by TILs. To further explore this, we treated seven breast
cell lines (derived from the four principal BC molecular sub-
types and normal breast) with individual interferons (a, b,
and g) to determine whether editing can be directly increased
AB
C
Figure 6. ADAR Involvement in Cell Prolifer-
ation and Apoptosis
(A) Western blot analysis of ADAR silencing after
shRNA lentiviral transduction in MDA-MB-231,
MCF7, and BT474 breast cancer cell lines.
(B) ADAR silencing statistically decreases cell
proliferation. Cell growth curves for ADAR-
knockdown cells (shRNA ADAR) and control cells
(shRNA control) in MDA-MB-231, MCF7, and
BT474 BC cell lines.
(C) ADAR silencing statistically increases cell
apoptosis. Illustration of the percentage of
apoptotic cells in ADAR-knockdown cells (shRNA
ADAR) and control cells (shRNA control) in
MDA-MB-231, MCF7, and BT474 BC cell lines.
Error bars depict SDs of three independent
experiments.by interferon. ADAR p150 protein expression increased with all
three interferons in all cell lines at each time point (Figures 5E
and S7), while p110 induction was weaker and less consistent.
The moderate but significant correlation between p110 and
STAT1 mRNA detected in primary tumors suggests that a small
amount of p110was induced (Figure S6). The same four cell lines
used to validate our A-to-I editing model were analyzed for p150
and p110 ADAR mRNA isoform expression levels, the editing
proportion of AZIN1 and the four most edited Alu regions previ-
ously selected. The mRNA levels for p110 and p150 isoforms
paralleled their protein expression (Figure S7). Moreover, editing
increased at all editable sites with all interferons in the four cell
lines (Figure 5F). Higher editing levels were observed at 2 or
5 days compared to untreated or 1 day. The induction of ADAR
and editing was lowest for IFN-g. These experiments confirm
that type-I interferon response affect A-to-I mRNA editing in
epithelial cells.
ADAR Is Involved in Cell Proliferation and Apoptosis in
Breast Cancer
Given that we have shown that both ADAR expression andmean
editing frequency were higher in breast tumors compared to
matched normal tissues, we aimed to further investigate ADAR’s
role on cell proliferation, migration, and apoptosis. To that pur-
pose, ADAR expression was stably knocked down in threeCell Reports 13, 277–289,representative BC cell lines (MDA-MB-
231, MCF7, and BT474) using small
hairpin RNA (shRNA) lentiviral particles
(shRNA ADAR). The three cell lines were
also transduced with scramble shRNA
lentiviral particles (shRNA control) as a
negative control for the functional experi-
ments. ADAR silencing was confirmed by
western blot analysis (Figure 6A).
To assess the role of ADAR in cell pro-
liferation, MTT assays were performed.
These experiments showed that ADAR
silencing led to a statistically significant
decrease in cell proliferation (shRNA
ADAR) compared to the control cells(shRNA control) in all cell lines (Figure 6B). These results suggest
that ADAR promotes cell proliferation. No significant effect of
ADAR silencing was found on cell migration. The role of ADAR
in apoptosis was investigated using Annexin V assays. ADAR
silencing led to a statistically significant increase in cell
apoptosis (shRNA ADAR) compared to the control cells (shRNA
control) in all cell lines (Figure 6C) suggesting that ADARmay act
as an anti-apoptotic factor.
The Role of ADAR Copy-Number Gains and Interferon
Responses in Other Cancers
ADAR amplification is frequent in human cancers (Figure 7) and
inflammatory responses are pervasive in this disease. This infor-
mation led us to investigate whether these two factors were
related to ADAR expression in 4,480 cancers from The Cancer
Genome Atlas (TCGA, http://cancergenome.nih.gov/) for which
sample-matched expression and copy-number profiles were
available. The representative analyses shown in Figures 5B
and 5C were reproducible across the TCGA data set, which
spanned 20 types of cancer from 16 organs (Figure 7). Overall,
ADAR expression was consistently associated with both ADAR
copy number and STAT1 expression. Similar to BC, adjusting
ADAR expression for ADAR copy number increased the correla-
tion between ADAR and STAT1 for all except pancreatic, kidney,
and thyroid tumors. The frequency of ADAR amplification wasOctober 13, 2015 ª2015 The Authors 285
Log2 (RPKM) Frequency (%) ρ -Log10 (p)Log2 (RPKM)
N ADAR expression ADAR DNA
losses and gains
STAT1 expression Correlation of
STAT1 vs ADAR expression
STAT1 vs CN-adj. ADAR expression
Figure 7. ADAR Amplification and the Interferon Response Predict ADAR Expression in Human Cancers
We included all TCGA data sets and tumors (see ‘‘N’’ column) for which both copy-number and RNA-seq expression data (pipeline v.3) were available. Data sets
are ordered by decreasing median ADAR expression (top to bottom). The three leftmost plots depict the distributions of ADAR expression, ADAR DNA copy
number, and STAT1 expression across each data set. The two rightmost bar plots extend to TCGA data the calculation presented for our data in Figures 5B and
5C. In most cancers, adjusting ADAR expression for ADAR copy number increases the Spearman correlation, r, with STAT1 (cf. the dark blue bars to the light
blue bars).low in kidney and thyroid tumors, therefore correcting for ADAR
copy number had a limited effect. These data suggest that ADAR
expression could be principally driven by interferon in these two
types of cancer. Inmost cancers, however, the editing process is
driven by both type I interferon and ADAR copy-number amplifi-
cation. A correlation between ADAR copy number and ADAR
expression has also been recently reported in esophageal can-
cer (Qin et al., 2014).
DISCUSSION
The magnitude of A-to-I editing in cancer as well as the mecha-
nisms controlling and regulating the A-to-I editing machinery are
currently unknown. To address both points, we performed a
survey on RNA editing in cancer by profiling dozens of BCs
and matched healthy breast tissues. The sample size of this
study opened a window on principles governing A-to-I editing
that were previously out of reach. A significant finding from our
study was the demonstration that the same sites are edited in
normal and tumor breast tissues as well as in several BC cell
lines. We further showed that while the editing frequency profiles
are correlated across tissues and BC cell lines, the frequency of
editing is significantly higher in tumors compared to their
matched normal breast tissues. High editing frequencies are de-
tected in samples with high ADAR expression. These data pro-
vide the basis for our A-to-I editing model, where increases in
ADAR expression increase the editing frequency of all editable
positions in the transcriptome. We successfully validated this286 Cell Reports 13, 277–289, October 13, 2015 ª2015 The Authorsmodel in BC cell lines and showed that ADAR control of site-
specific editing frequency can be approximated with the
logistic model. ADAR’s site-specific activity, that we call edit-
ability, is partly influenced by the biophysics of interactions
between nucleotides in the surrounding RNA sequences and
their duplex partnering with ADAR and can be estimated from
dose-response experiments. Finally, we showed that ADAR
expression is controlled by 1q amplification and inflammation
in human cancers.
In our study, longer ADAR induction times and/or deeper
sequencing coverage increased the number of editing sites de-
tected. Interestingly, no plateau was reached at the depths we
investigated, with up to 33 107 aligned reads per sample. A pre-
vious studymade a similar observation using a coverage of up to
5 3 108 mRNA reads/sample, where no plateau was reached
despite >140,000 A-to-I sites detected in the Alu’s (Ramaswami
et al., 2012). A hundred million sites could be edited in humans
(Bazak et al., 2014b). Differences in number of edited sites be-
tween the cited works and the present study could be due to
the cell type analyzed (e.g., lymphoblastoid cell line versus
breast tissues/cell lines) and the DNA (e.g., whole-genome
versus coding sequences and their neighborhood) and/or RNA
sequencing strategies (Table S4). For example, several studies
used the GM12878 and the YH (also known as SRA043767)
cell lines for which the transcriptomes were sequenced at the
outstanding depth of 0.5–1.2 billions reads and compared to
the matched whole-genome sequence. In these studies, the
number of editing sites, ranging from 20,000 to 2 million, is
commensurate to the number of callable bases. Conversely, the
studies with lower individual transcriptome coverages report
less editing sites, like ours (560 sites) and Bahn et al. (2012)
(5,965 sites). Bahn et al. had access to the full genome
sequence, while we had access only to the coding DNA
sequence (CDS) regions and their neighborhood. In addition,
the detection pipeline specificity versus sensitivity trade-off
may also play a role. Most previous studies used the A > G ratio
as a surrogate for error rates; i.e., they assumed that A-to-I is the
only significant RNA editing type and that all A > G RDDs are
bona fide editing events. The A > G rate in Alu regions is 80%
in Bazak et al. (2014a, 2014b), 90% in Peng et al. (2012), 96%
in Ramaswami et al. (2012), and 100% in our study. Our pipeline
is therefore more conservative according to this criterion, and
consequently less putative editing sites were detected. It is
anticipated that a large number of additional A-to-I editing sites
beyond those identified here remain to be discovered in BC. The
data presented here clearly demonstrate that A-to-I editing is a
pervasive phenomenon in cancer and suggest that it is a major
source of mRNA sequence variability in breast and potentially
other types of cancer (Paz-Yaacov et al., 2015; Han et al.,
2015). Editing has the potential to significantly impact tran-
scriptional regulation and cellular functions in tumor cells.
Indeed, our in vitro studies have shown that ADAR silencing
decreases cell proliferation and promotes apoptosis supporting
the potential carcinogenic role of ADAR and consequently A-to-I
editing in BC.
Multiple studies are revealing that aberrant expression of
ADAR and APOBEC families of enzymes occurs in many human
diseases, including cancer. Since the first studies implementing
the sequencing technology in humans, ADAR appeared to be
one of the highest overexpressed genes in BC, and its recoding
potential started to emerge (Shah et al., 2009). More recent
works have shown that in breast and other tumor types muta-
tional signatures are associated with APOBEC family proteins
(Alexandrov et al., 2013; Nik-Zainal et al., 2012) with evidence
that APOBEC-mediated mutagenesis is highly active in human
cancers (Burns et al., 2013; Roberts et al., 2013; Swanton
et al., 2015; Zhang et al., 2015). Although the relevance of
ADARs and RNA editing in cancer just begins to be recognized
(Avesson and Barry, 2014; Han et al., 2014; Mo et al., 2014; Sal-
ameh et al., 2015; Witkin et al., 2015), the link between A-to-I
editing by ADAR and the type I interferon response shown in
our study suggests that the cancer immune response can influ-
ence ADAR’s activity, as shown in other systems. A significant
role for ADAR is further supported by our demonstration that
its expression is significantly upregulated by ADAR copy-num-
ber gains in breast (up to 75%) and other cancers (up to
70%). Overall, these data highlight the potential magnitude of
A-to-I RNA editing in tumors and thereby the possibility for
large-scale clinical implications. RNA editing and/or APOBEC-
mediated mutagenesis could shape the immunogenicity of the
tumor and thereby directly affect anti- and/or pro-tumor im-
mune responses. RNA editing itself, the processes it regulates
and its potential to differentially direct activities in response
to the chronic inflammatory tumor microenvironment, may
have important implications for clinical progression in breast
and other cancers.CThe widespread editing we observed, in combination with the
conservation of editing sites detected across tissues and pa-
tients, suggests there might be clinical and therapeutic implica-
tions for awide range of cancer patients. However, modulation of
editing at an individual site is entangled with many processes.
The model we established for A-to-I editing implies that modula-
tion of ADAR will also affect all editable sites in expressed tran-
scripts. In addition, ADAR has been shown to influence miRNA
processing (Heale et al., 2009; Ota et al., 2013; Shoshan et al.,
2015; Tomaselli et al., 2013; Yang et al., 2006), to control
mRNA transcript stability (Wang et al., 2013) and to affect several
RNA processing pathways (Bahn et al., 2015). Finally, variation of
ADAR expression in vivo will possibly be associated with modi-
fication of the hundreds of genes located on 1q and/or controlled
by interferon. Determining whether increasing A-to-I editing
limits or enhances cancer progression will need to take into ac-
count all of these potential variables. More research is needed to
identify the critical editing sites, establish their potential as
markers of cancer evolution, and investigate them as a new class
of therapeutic targets.
EXPERIMENTAL PROCEDURES
The study has been approved by the Institut Jules Bordet Ethics Committee
(approval number: CE1967). The methods are fully detailed in the Supple-
mental Experimental Procedures. In brief, the exome and transcriptome of
58 well-characterized BC samples representing the four main known sub-
types based on immunohistochemistry, namely, TN, HER2+, luminal A, and
luminal B, and ten matched normal samples were profiled using exome
sequencing and RNA-seq in paired-endmode on the Illumina HiSeq 2000 plat-
form. Gene expression and SNPs profiles were obtained with Affymetrix
HG-U133 Plus 2.0 Array chips and Affymetrix Genome-Wide Human SNP
Arrays 6.0 for 57 and 49 tumor samples, respectively. RNA reads obtained
from RNA-seq were aligned simultaneously on the human genome and all
known exonic junctions. Variant calls were submitted to a series of filters
limiting artifact associated with RNA-seq. The identified RNA-DNA differences
(RDDs) were validated in an independent cohort of 15 BC samples; moreover,
few events as well as their editing frequencies were validated using an inde-
pendent technology (Roche FLX sequencer). The effect of interferon (IFN) on
ADAR expression and editing was evaluated on six BC cell lines and one
immortalized, non-transformed mammary epithelial cell line, MCF-10A. Cell
lines were treated for 1, 2, or 5 days with IFN a, b, or g. The effect of treatment
on ADAR p110 and p150 protein and gene expression levels were evaluated
quantifying the immunoblot signals and qRT-PCR data, respectively, while
the effect of IFN treatment on editing distribution and frequency was investi-
gated using amplicon sequencing (Roche FLX sequencer). In each sample,
the mean editing frequency was correlated with clinico-pathological parame-
ters and the expression of ADAR. The intracellular localization of ADAR was
defined using immunohistochemistry. The association between editing and
ADAR amplification and/or a surrogate of interferon response (STAT1 expres-
sion) was evaluated in breast and 19 additional cancer types obtained from
TCGA. Finally, the effect of ADAR knockdown on cell proliferation, migration,
and apoptosis was evaluated in three representative BC cell lines transduced
with shRNA lentiviral particles.
ACCESSION NUMBERS
Sequencing and SNPs array data obtained from the enrolled patients are
archived at European Genome-phenome Archive, https://www.ebi.ac.uk/
ega, under accession number EGAS00001000495; amplicon sequencing
data obtained from cell lines are archived at European Nucleotide Archive,
http://www.ebi.ac.uk/ena, under study accession number ERP004253; gene
expression array data are archived at the NCBI GEO, http://www.ncbi.nlm.ell Reports 13, 277–289, October 13, 2015 ª2015 The Authors 287
nih.gov/geo, under accession number GSE43358. Clinical information, results
of sequence and arrays preprocessing, and biological assays are available in
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